Skip to main content
. 2014 Jun 7;14:105. doi: 10.1186/1471-230X-14-105

Table 4.

Multivariate analyses of factors associated with recurrence-free survival (RFS) in GIST patients with adjuvant imatinib therapy (*, P < 0.05)

Variable RFS hazard ratio (95% Cl) P value
Tumor size (≤10, > 10 cm)
0.801 (0.222-2.889)
0.736
Mitosis count (≤10, > 10/50 HPF)
1.944 (0.546-6.913)
0.307
Serosal invasion (Yes, No) 3.549 (1.047-12.025) 0.043*